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Introduction
• Two themes to this talk
– What we have learnt from our body of research 
into the last year of life
– With a focus on study designs incorporating 
choice
Overtreatment in the last year of life
• Research lead by A/Prof Cardona
• identifiable and potentially preventable
2017:  Aus 3.7million aged 65+ years;   QLD 720,000
22             
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2018:
1 in 5 emergency 
presentations
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1 in 7 could 
have been 
managed 
by a GP
AUS 85+y.o. 
Resuscitation: 
2,650 
What is overtreatment
near the end of life?
• Any medical, surgical treatments 
or additional testing or 
hospitalisations that will not 
change management or 
prognosis and can potentially 
cause harm 
• This overuse of treatments 
inflicts unnecessary patient 
suffering, creates false hope of 
patient survival and frustration 
among clinical staff, and 
generates unsustainable costs. 
What can we do 
to reduce it? 
1. Tools for 
predicting 
people at risk 
of death within 
the year are 
available for 
free. 
2. Timely honest 
conversations on non-
aggressive options 
using decision aids 
and advance health 
directives. 
NZ Advance Care Planning Guide
Is choice beneficial?
• Shared decision making & decision aids increasingly important
• Patients weigh up the harms and benefits and make a 
decision for treatment in line with their values and beliefs
• Important to have evidence of when treatment choice is 
beneficial and when it may be harmful 
– Does patient choice of treatment change outcomes?
• How do we measure the effect of choice?
Randomised trials incorporating patient choice
• Standard RCTs do not allow for the investigation of participant preferences 
for treatment
• 2-stage design with participants randomised to choice or no choice
• Analysis method developed by Rucker (1989) allows estimation of:
Treatment effect: standard randomised comparison of the A vs B
Selection effect: the comparison of people who prefer treatment A with 
those who prefer B
Preference effect: the comparison of people who receive their preferred 
treatment with those who do not (i.e. the effect of choice)
Design incorporating treatment choice
Analysis
• Uses information in the choice arm to estimate 
the mean outcomes for people who did or did 
not receive their preferred treatment
• Previous use of this design has shown large 
effects of preference that were not seen in the 
traditional analysis
McCaffery KJ, Irwig L, Turner R, et al. BMJ.  2010;340:b4491.
McCaffery KJ, Turner R, Macaskill P, et al. Med Decis Making.  2011;31:229-36.
When should I use this design?
• Addition of a choice arm (to estimate preference & selection 
effects) reduces power to detect the treatment effect (if the 
total sample size is not increased) 
• The design appeals when:
– preference is important
– treatment effect is known to be small
• Treatments should be (nearly) equally preferred
– This preference rate very important in determining sample 
size
Conclusions
• Need to identify older people at increased risk 
of dying sooner (e.g. CriSTAL tool)
• Informed decision making
• Evidence from two-stage RCT design that 
choice is beneficial
• More conversations earlier
